Protection against titanium particle-induced osteoclastogenesis by cyclooxygenase-2 selective inhibitor

Area of Science:

• Biomedical Engineering
• Orthopedic Research
• Immunology

Background:

• Aseptic loosening in total joint arthroplasty is commonly caused by wear particle-induced osteoclastogenesis.
• Cyclooxygenase-2 (COX-2) regulates prostaglandin E2 (PGE2) synthesis and is implicated in osteoclast differentiation, but its role in wear particle-induced osteoclastogenesis is unclear.

Purpose of the Study:

• To investigate the role of COX-2 in regulating osteoclast differentiation stimulated by titanium (Ti) particles in RAW264.7 cells.

Main Methods:

• Stimulated RAW264.7 cells with Ti particles and receptor activator of nuclear factor kappa B ligand (RANKL).
• Assessed COX-2 expression and PGE2 levels.
• Utilized celecoxib (COX-2 inhibitor) and exogenous PGE2.
• Performed quantitative real-time polymerase chain reaction (qRT-PCR) for gene expression analysis.

Main Results:

• COX-2 expression was observed during early differentiation stages.
• Celecoxib treatment reduced PGE2 levels and inhibited osteoclast differentiation (TRAP+ cells).
• Celecoxib suppressed mRNA expression of RANK, cathepsin K, TRAP, and NFATc1.
• Exogenous PGE2 counteracted the inhibitory effects of celecoxib.

Conclusions:

• COX-2 dependent PGE2, induced by RANKL and Ti particles, is essential for osteoclastogenesis.
• Inhibiting COX-2 to reduce PGE2 production presents a promising therapeutic strategy for wear particle-induced osteoclastogenesis.